INKT Stock Analysis: Buy, Sell, or Hold?
INKT - MiNK Therapeutics, Inc. Common Stock
$10.51
-0.54 (-4.89%)
▼
5d:
-6.08%
30d:
-18.78%
90d:
-4.8%
HOLD
LOW Confidence
Analysis Updated: May 14, 2026 12:00 AM ET
Earnings: May 21, 2026
6d
Get Alerted When INKT Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
1 traders called INKT this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
📊 HOLD: INKT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
📊 HOLD: INKT shows balanced signals. Fine to hold or accumulate slowly. Monitor for clearer direction.
In-depth Analysis How we analyze
Valuation Analysis: INKT is currently trading at $10.51, which is considered oversold relative to its 30-day fair value range of $10.74 to $12.62.
Technical Outlook: Technically, INKT is showing sideways momentum. The price is currently testing key support at $10.95. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.9% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $39.00 (+271.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Technical Outlook: Technically, INKT is showing sideways momentum. The price is currently testing key support at $10.95. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.9% recently.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. Wall Street analysts see significant upside, with an average price target of $39.00 (+271.1%). The stock is fairly positioned - fine to hold existing positions or accumulate slowly on dips, but not an urgent buy.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$10.74 -
$12.62
Company Quality Score
56/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
77.4%
All Signals
- BULLISH: Price oversold vs 30-day range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-4.9%)
- BULLISH: Trading 271.1% below Wall St target ($39.00)
- CAUTION: Recommendation downgraded due to -6.1% 5-day decline
Trading Range Analysis
30-Day Trading Range
$10.74 -
$12.62
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$10.95
Resistance Level
$12.42
Current Trend
Sideways
Technical data as of
May 14, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-3.05
Wall Street Target
$39.00
(+271.1%)
Share & Embed Analysis
Last updated: May 14, 2026 6:31 PM ET
Data refreshes hourly during market hours. Next update: 7:31 PM
Data refreshes hourly during market hours. Next update: 7:31 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is INKT showing a specific setup today?
Insider Activity (6 Months)
0
Buys
4
Sells
Net
INSIDERS SELLING
Recent Transactions
Barbara Ryan
SELL
1300 shares
2026-03-10
Barbara Ryan
SELL
200 shares
2026-03-09
Barbara Ryan
SELL
100 shares
2026-03-02
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
BMRN
Biomarin Pharmaceutical … |
STRONG BUY
29 analysts |
$91 | 63 BUY |
|
CYTK
Cytokinetics Inc |
STRONG BUY
21 analysts |
$104 | 60 BUY |
|
NRIX
Nurix Therapeutics Inc |
STRONG BUY
18 analysts |
$30 | 58 HOLD |
|
BHVN
Biohaven Pharmaceutical … |
STRONG BUY
16 analysts |
$22 | 54 HOLD |
|
RVMD
Revolution Medicines Inc |
STRONG BUY
12 analysts |
$181 | 59 HOLD |
